Scleroderma (Systemic Sclerosis) | Treatment Algorithms: Claims Data Analysis | US | 2022

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis underlie a high mortality rate. This report covers the complex array of treatments used to treat the disease; ILD and skin fibrosis are targeted with systemic immunosuppressants, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, and off-label biologics. We provide needed context for emerging players seeking to capitalize on the unmet needs in this underserved population.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
  • How has Boehringer Ingelheim’s Ofev been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of SSc patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Boehringer Ingelheim, Roche, GlaxoSmithKline, Bayer HealthCare, AbbVie 

Key drugs: Ofev, Esbriet, Rituxan and biosimilars, Adempas, calcium channel blockers, conventional oral immunosuppressants, corticosteroids, PDE-5 inhibitors, select biologics


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Login to access report